Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biologics company Bioventus has bought exclusive rights to Pfizer’s bone morphogenetic protein (BMP) portfolio of development programs and associated intellectual property, for an undisclosed sum.
Subscribe to our email newsletter
The acquired portfolio comprises a next-generation BMP, which is under development and has been designed to provide additional options to currently-marketed BMP products, as well as the rights to rhBMP-2 in indications and fields.
Additionally, Bioventus has also purchased an exclusive option to a BMP program for soft tissue indications.
Based on the agreement, Pfizer will transfer all existing development work for the BMP assets to Bioventus and to undertake certain early-development activities relating to the next-generation BMP.
While Pfizer has received an upfront payment and will be eligible to receive milestone payments and royalties on any sales, it has also agreed to manufacture rhBMP-2 and supply it to Bioventus.
Bioventus lead investor, Essex Woodlands founding partner and managing director Martin Sutter said, "This licensing agreement demonstrates the viability of the investment thesis underlying our participation in Bioventus.
"Developing the next-generation BMP will enable Bioventus to become a recognized leader in orthobiologics," Sutter added.